A closer look at chimeric antigen receptor specificity

Cytotherapy

Volumn 16, Issue 10, 2014, Pages 1323-1324

  Cruz, Conrad Russell ^a  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; CINTREDEKIN BESUDOTOX; CONNECTIN; EPITOPE; GAMMA INTERFERON; INTERLEUKIN 13 RECEPTOR ALPHA1; INTERLEUKIN 13 RECEPTOR ALPHA2; MELANOMA ANTIGEN 3;

AMINO ACID SUBSTITUTION; ANTIGEN RECOGNITION; CANCER IMMUNOTHERAPY; CELL THERAPY; CROSS REACTION; GLIOBLASTOMA; GLIOMA; HUMAN; NONHUMAN; NOTE; PROTEIN EXPRESSION; T LYMPHOCYTE;

EID: 84908478840     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2014.08.002     Document Type: Note

References (11)

1. Maus M.V., Grupp S.A., Porter D.L., June C.H. Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood 2014, 123:2625-2635.
2. Mintz A., Gibo D.M., Slagle-Webb B., Christensen N.D., Debinski W. IL-13Ralpha2 is a glioma-restricted receptor for interleukin-13. Neoplasia 2002, 4:388-399.
3. Krebs S., Chow K.K., Yi Z., Rodriguez-Cruz T., Hegde M., Gerken C., et al. Tcells redirected to interleukin-13Ralpha2 with interleukin-13 mutein-chimeric antigen receptors have anti-glioma activity but also recognize interleukin-13Ralpha1. Cytotherapy 2014, 16:1121-1131.
4. Buning H., Uckert W., Cichutek K., Hawkins R.E., Abken H. Do CARs need a driver's license? Adoptive cell therapy with chimeric antigen receptor-redirected T cells has caused serious adverse events. Hum Gene Ther 2010, 21:1039-1042.
5. Morgan R.A., Yang J.C., Kitano M., Dudley M.E., Laurencot C.M., Rosenberg S.A. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010, 18:843-851.
6. Brichard V.G., Louahed J., Clay T.M. Cancer regression and neurological toxicity cases after anti-MAGE-A3 TCR gene therapy. JImmunother 2013, 36:79-81.
7. Linette G.P., Stadtmauer E.A., Maus M.V., Rapoport A.P., Levine B.L., Emery L., et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 2013, 122:863-871.
8. Kawakami M., Leland P., Kawakami K., Puri R.K. Mutation and functional analysis of IL-13 receptors in human malignant glioma cells. Oncol Res 2001, 12:459-467.
9. Kunwar S., Prados M.D., Chang S.M., Berger M.S., Lang F.F., Piepmeier J.M., et al. Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. JClin Oncol 2007, 25:837-844.
10. Kahlon K.S., Brown C., Cooper L.J., Raubitschek A., Forman S.J., Jensen M.C. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res 2004, 64:9160-9166.
11. Kong S., Sengupta S., Tyler B., Bais A.J., Ma Q., Doucette S., et al. Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptor-modified T cells. Clin Cancer Res 2012, 18:5949-5960.